Tariffs just got personal—for patents.
President Donald Trump signed an executive order yesterday, “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States,” that cranks tariffs to 100% on patented drugs and ingredients from 17 major players like AbbVie, Bristol Myers Squibb, and Novartis. Unless they onshore production pronto. It’s not subtle. Within 120 days, imports face the full hit—or a reduced 20% rate if they commit, ramping to 100% over four years without most-favored-nation pricing for U.S. buyers.
Why Target Patented Pharma Now?
Look, pharma’s supply chains snake through China and India—80% of active ingredients come from abroad, per FDA data. Trump’s move isn’t random; it’s a cudgel against offshoring that’s left America vulnerable, especially post-COVID shortages. Market dynamics scream opportunity here: U.S. manufacturing capacity sits idle at 28%, according to the Department of Commerce. But here’s the sharp take—this smells like political red meat ahead of midterms, dressed as national security.
Drugmakers’ stocks dipped 2-4% on the news. AbbVie’s Humira clones? Suddenly pricier to import. Novartis? Same story. And patents? They’re the linchpin. Tariffs bite only patented stuff, forcing holders to rethink global strategies. Commit to onshoring, or watch generics flood cheaper markets while you bleed margins.
A single sentence from the EO nails it:
establishing tariffs of 100% on imports of patented pharmaceuticals and their ingredients to be levied in the next 120 days against 17 drugmakers including AbbVie, Bristol Myers Squibb, Gilead, Novartis and Novo Nordisk unless they commit to agreements to onshore production within the United States.
That’s the hammer. No wiggle room.
And it’s already rippling. Elon Musk’s SpaceX chatting with Saudi PIF for a $5B stake retention? Peripheral, but shows capital flight risks in tense IP-trade wars. Meta’s 200 layoffs? Tech belt-tightening amid uncertainty.
Will These Tariffs Actually Reshore Factories?
Short answer: Doubt it, fully. History echoes—Trump’s 2018 steel tariffs spurred some U.S. builds, but pharma’s different. Building sterile facilities costs $1-2 billion each, takes 3-5 years. Novo Nordisk’s Ozempic? Demand’s exploding; they can’t pivot overnight.
Data point: Post-Section 301 China tariffs, pharma imports dropped just 5%, per U.S. Trade Rep stats. Companies rerouted via Vietnam, Mexico. Expect the same. My unique angle? This previews a patent reshoring arms race—like the CHIPS Act for semis, but for pills. Bold prediction: By 2028, we’ll see $50B in new U.S. pharma plants, but only if tax credits pair with these sticks. Otherwise, it’s PR spin from drug lobbyists crying foul.
But wait—MFN pricing? That’s the carrot. American consumers get drugs at the lowest global price. Smart, if enforced. Gilead’s antivirals could drop 30%, modeling off Medicare negotiations.
Skeptical? Yeah. Enforcement’s DOJ turf, and they’ve got FRAND preferences elsewhere (more later).
Federal Circuit drops a bomb too.
In Fortress Iron v. Digger Specialties, CAFC affirmed invalidation of fencing patent claims—co-inventor omitted, couldn’t be fixed under 35 U.S.C. § 256. The unnamed guy? A “party concerned,” but MIA. Boom—claims die.
Does TikTok’s IPR Fumble Signal RPI Crackdown?
USPTO Director John Squires vacated seven TikTok IPRs against Cellspin Soft patents. Reason? TikTok failed to prove Chinese government entities weren’t real-parties-in-interest (RPI). Cites Tianma Microelectronics precedent, extending Return Mail’s U.S. gov ban to foreign ones.
TikTok—ByteDance’s baby—challenges U.S. patents routinely. But Squires isn’t playing: “TikTok did not carry its burden to establish that a foreign government… was not a real-party-in-interest.”
Market play: Heightens scrutiny on China-linked filers. PTAB institutions down 15% YOY for foreign petitioners, per Docket Navigator. Sharp position—this bolsters U.S. patentees against state-backed trolls, but slows IPRs overall. Good for innovation? Marginally. TikTok loses use in licensing wars.
Fourth Circuit bars Clear Touch’s IP claims via res judicata—state dismissal with prejudice killed federal trademarks. Clean, but warns: Settle smart, or courts will.
DOJ’s Dina Kallay at LeadershIP pushes FRAND standards over non-FRAND consortia. Antitrust angle: FRAND keeps markets open.
China cozies with Hungary, Finland on IP—WIPO-style collab.
Here’s the thing—these aren’t isolated barks.
Trump’s tariffs collide with inventorship traps and RPI hurdles, squeezing IP value. Pharma patents, once global shields, now tariff magnets. Unique insight: Parallels Smoot-Hawley 1930—tariffs spiked, but retaliation crushed exports. Pharma giants export $100B yearly; expect EU countermeasures, hiking insulin prices everywhere.
Data-driven: Onshoring could add 50K jobs (PhRMA est.), but at 10-20% cost hikes short-term. Does it make sense? For voters, yes. For shareholders, risky bet.
Corporate hype calls it “America First innovation.” Nah—it’s coercion with patents as collateral.
Why Does TikTok RPI Matter for Tech Patents?
TikTok’s vacatals? Precedent-setter. PTAB’s Tianma rule means proving no gov puppet strings—hard for PRC firms. U.S. patentees win 65% of IPR trials anyway; this tips to 70%+. Developers rejoice: Fewer cheap challenges.
But sprawl: Social media patents (Cellspin’s? Likely video tech) get breathing room. Broader? Huawei, ZTE face same.
Barks fade—SpaceX-Saudi, Meta cuts—but core bites reshape IP markets.
Position: Tariffs make sense directionally, execution’s the killer.
🧬 Related Insights
- Read more: Anthropic Quietly Abandons Its Core Safety Promise as Competition Heats Up
- Read more: UK’s Social Media Kid Ban: Minister’s Blank Check to Censor
Frequently Asked Questions
What does Trump’s pharma tariff executive order do?
Imposes 100% tariffs on patented drug imports unless companies onshore production and offer MFN pricing to U.S. consumers—hits 17 majors starting in 120 days.
Why did USPTO vacate TikTok’s IPR petitions?
TikTok couldn’t prove Chinese gov entities weren’t RPIs, per Tianma precedent banning foreign govs from IPRs.
Can omitted inventors still save patents?
Only if correctable under §256—Fortress Iron says no if the co-inventor’s unreachable; claims invalidate.
